HIV/AIDS

The Board took note of the final report of its Working Group and approved the overall strategic direction for the transition.

In 2025, an estimated 11.5 million people living with HIV worldwide were aged 50 and above, representing approximately 29% of the global population living with the virus.

The partnership complements existing mechanisms for supplying generic versions of lenacapavir and aims to address gaps in HIV prevention across the region.

Lenacapavir has demonstrated almost 100% efficacy in preventing HIV infection in clinical trials, giving Zambia an additional prevention option alongside existing HIV services.

The agreement covers 129 countries, including all African nations, and gives Aspen rights across both public and private healthcare sectors.

The replenishment will restore supplies at facilities in Tshwane, Johannesburg and Sedibeng that experienced temporary shortages after demand exceeded initial projections following the programme’s rollout in June 2026.

Community advocacy contributed to an Indonesian Ministry of Health regulation that allows young people under 18 to be accompanied not only by parents but also by community members and outreach workers when accessing HIV testing.

The 95-95-95 targets aim for 95% of people living with HIV to know their status, 95% of those diagnosed to receive antiretroviral treatment, and 95% of those receiving treatment to achieve viral suppression.

The licensing agreement will allow UCL to manufacture and supply generic alimatravir in African countries and other markets covered by the agreement, subject to successful clinical development and regulatory approval.